Real-world effectiveness and safety of dapagliflozin therapy added to a GLP1 receptor agonist in patients with type 2 diabetes

To evaluate the effectiveness and safety of a sodium –glucose cotransporter-2 (SGLT-2) inhibitor, dapagliflozin, in patients with type 2 diabetes mellitus (T2DM) and background glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy.

Source: Nutrition, Metabolism, and Cardiovascular Diseases : NMCD - November 21, 2016 Category: Nutrition Authors: J.J. Gorgojo-Mart ínez, C. Serrano-Moreno, A. Sanz-Velasco, G. Feo-Ortega, F. Almodóvar-Ruiz Source Type: research